SK2292003A3 - Tricyclic antitumor compounds being farnesyl protein transferase inhibitors - Google Patents

Tricyclic antitumor compounds being farnesyl protein transferase inhibitors Download PDF

Info

Publication number
SK2292003A3
SK2292003A3 SK229-2003A SK2292003A SK2292003A3 SK 2292003 A3 SK2292003 A3 SK 2292003A3 SK 2292003 A SK2292003 A SK 2292003A SK 2292003 A3 SK2292003 A3 SK 2292003A3
Authority
SK
Slovakia
Prior art keywords
compound
mmol
solution
preparation
compounds
Prior art date
Application number
SK229-2003A
Other languages
English (en)
Slovak (sk)
Inventor
George F Njoroge
Bancha Vibulbhan
Alan B Cooper
Timothy Guzi
Dinanath F Rane
Keith P Minor
Ronald J Doll
Viyyoor Moopil Girijavallabhan
Bama Santhanam
Patrick A Pinto
Hugh Y Zhu
Kartik M Keertikar
Carmen S Alvarez
Robert W Bishop
James Wang
Jagdish A Desai
John J Baldwin
Ge Li
Chia-Yu Huang
Ray A James
Original Assignee
Schering Corp
Pharmacopeia Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp, Pharmacopeia Inc filed Critical Schering Corp
Publication of SK2292003A3 publication Critical patent/SK2292003A3/sk

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D221/00Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04Ortho- or peri-condensed ring systems
    • C07D221/06Ring systems of three rings
    • C07D221/16Ring systems of three rings containing carbocyclic rings other than six-membered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SK229-2003A 2000-08-30 2001-08-28 Tricyclic antitumor compounds being farnesyl protein transferase inhibitors SK2292003A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22918300P 2000-08-30 2000-08-30
PCT/US2001/026792 WO2002018368A1 (en) 2000-08-30 2001-08-28 Tricyclic antitumor compounds being farnesyl protein transferase inhibitors

Publications (1)

Publication Number Publication Date
SK2292003A3 true SK2292003A3 (en) 2003-08-05

Family

ID=22860141

Family Applications (1)

Application Number Title Priority Date Filing Date
SK229-2003A SK2292003A3 (en) 2000-08-30 2001-08-28 Tricyclic antitumor compounds being farnesyl protein transferase inhibitors

Country Status (27)

Country Link
US (1) US20020198216A1 (pt)
EP (1) EP1313725B1 (pt)
JP (1) JP2004513885A (pt)
KR (1) KR20030034161A (pt)
CN (1) CN100384837C (pt)
AR (1) AR033680A1 (pt)
AT (1) ATE359281T1 (pt)
AU (2) AU8845101A (pt)
BR (1) BR0113675A (pt)
CA (1) CA2420673A1 (pt)
CO (1) CO5640109A2 (pt)
DE (1) DE60127846T2 (pt)
EC (1) ECSP034494A (pt)
ES (1) ES2284686T3 (pt)
HK (1) HK1054548B (pt)
HU (1) HUP0302942A3 (pt)
IL (1) IL154528A0 (pt)
MX (1) MXPA03001849A (pt)
NO (1) NO20030918L (pt)
NZ (1) NZ524246A (pt)
PE (1) PE20020486A1 (pt)
PL (1) PL361103A1 (pt)
RU (1) RU2293734C9 (pt)
SK (1) SK2292003A3 (pt)
TW (1) TWI268280B (pt)
WO (1) WO2002018368A1 (pt)
ZA (1) ZA200301545B (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7342016B2 (en) * 2000-08-30 2008-03-11 Schering Corporation Farnesyl protein transferase inhibitors as antitumor agents
US7312237B2 (en) * 2001-03-14 2007-12-25 Bristol-Myers Squibb Co. Combination of epothilone analogs and chemotherapeutic agents for the treatment of prolilferative diseases
WO2003030908A2 (en) * 2001-10-09 2003-04-17 The University Of Cincinnati Inhibitors of the egf receptor for the treatment of thyroid cancer
HUP0402401A2 (hu) * 2001-11-30 2005-03-29 Schering Corp. Rák kezelésére szolgáló eljárások egy FPT inhibitor és daganatellenes szerek felhasználásával
CN1849122A (zh) * 2001-12-03 2006-10-18 先灵公司 Fpt抑制剂与至少两种抗肿瘤药在治疗癌症中的用途
US20030195192A1 (en) * 2002-04-05 2003-10-16 Fortuna Haviv Nicotinamides having antiangiogenic activity
US20040014744A1 (en) * 2002-04-05 2004-01-22 Fortuna Haviv Substituted pyridines having antiangiogenic activity
WO2004094409A1 (en) 2003-03-27 2004-11-04 Lankenau Institute For Medical Research Novel ido inhibitors and methods of use
JP2006526662A (ja) * 2003-06-05 2006-11-24 アシュカル,チャールズ 過増殖性細胞疾患を治療する方法
US20070036795A1 (en) * 2003-06-09 2007-02-15 Samuel Waksal Method of inhibiting receptor tyrosine kinases with an extracellular antagonist and an intracellular agonist
EP1660477B1 (en) * 2003-08-07 2008-12-10 Schering Corporation Novel farnesyl protein transferase inhibitors as antitumor agents
US7592466B2 (en) 2003-10-09 2009-09-22 Abbott Laboratories Ureas having antiangiogenic activity
AU2005319182A1 (en) * 2004-12-21 2006-06-29 Schering Corporation Novel farnesyl protein transferase inhibitors as antitumor agents
WO2010006432A1 (en) * 2008-07-14 2010-01-21 Queen's University At Kingston Pharmaceutical compositions comprising ret inhibitors and methods for the treatment of cancer

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5089496A (en) * 1986-10-31 1992-02-18 Schering Corporation Benzo[5,6]cycloheptapyridine compounds, compositions and method of treating allergies
US5719148A (en) * 1993-10-15 1998-02-17 Schering Corporation Tricyclic amide and urea compounds useful for inhibition of g-protein function and for treatment of proliferative diseases
PE92098A1 (es) * 1996-07-31 1998-12-31 Schering Corp N-cianoiminas triciclicas utiles como inhibidores de transferasa de proteina farnesilo
US6071907A (en) * 1996-09-13 2000-06-06 Schering Corporation Tricyclic compounds useful as FPT inhibitors
US5925648A (en) * 1997-07-29 1999-07-20 Schering Corporation Tricyclic N-cyanoimines useful as inhibitors of a farnesyl-protein transferase
BR9916328A (pt) * 1998-12-18 2001-10-02 Schering Corp Inibidores de transferase de farnesila

Also Published As

Publication number Publication date
DE60127846D1 (en) 2007-05-24
EP1313725A1 (en) 2003-05-28
CN1471524A (zh) 2004-01-28
NO20030918D0 (no) 2003-02-27
HUP0302942A2 (hu) 2003-12-29
ZA200301545B (en) 2004-06-22
HUP0302942A3 (en) 2007-02-28
JP2004513885A (ja) 2004-05-13
ECSP034494A (es) 2003-04-25
MXPA03001849A (es) 2003-06-04
ATE359281T1 (de) 2007-05-15
WO2002018368A1 (en) 2002-03-07
RU2293734C2 (ru) 2007-02-20
IL154528A0 (en) 2003-09-17
CO5640109A2 (es) 2006-05-31
HK1054548B (zh) 2007-10-18
EP1313725B1 (en) 2007-04-11
PE20020486A1 (es) 2002-06-14
CN100384837C (zh) 2008-04-30
AU2001288451C1 (en) 2008-03-06
TWI268280B (en) 2006-12-11
AR033680A1 (es) 2004-01-07
PL361103A1 (en) 2004-09-20
NZ524246A (en) 2004-11-26
AU2001288451B2 (en) 2007-05-24
US20020198216A1 (en) 2002-12-26
AU8845101A (en) 2002-03-13
NO20030918L (no) 2003-04-29
HK1054548A1 (en) 2003-12-05
BR0113675A (pt) 2003-06-24
DE60127846T2 (de) 2008-03-06
KR20030034161A (ko) 2003-05-01
ES2284686T3 (es) 2007-11-16
RU2293734C9 (ru) 2007-10-10
CA2420673A1 (en) 2002-03-07

Similar Documents

Publication Publication Date Title
DE69831937T2 (de) Bicyclische protein-farnesyl-transferase inhibitoren
AU2008294410B2 (en) Compounds with anti-cancer activity
SK2292003A3 (en) Tricyclic antitumor compounds being farnesyl protein transferase inhibitors
US20030229099A1 (en) Novel farnesyl protein transferase inhibitors as antitumor agents
US20040006087A1 (en) Method of treating cancer using FPT inhibitors and antineoplastic agents
US7342016B2 (en) Farnesyl protein transferase inhibitors as antitumor agents
WO2001021169A1 (fr) Antagonistes de l'hormone de concentration de la melanine
AU2001288451A1 (en) Tricyclic antitumor compounds being farnesyl protein transferase inhibitors
JP2005525356A5 (pt)
EP0989983B1 (en) Benzpyrido cycloheptane compounds useful for inhibition of farnesyl protein transferase
EP1660477A1 (en) Novel farnesyl protein transferase inhibitors as antitumor agents
US7635697B2 (en) Farnesyl protein transferase inhibitors and methods for treating proliferative diseases
SK7592001A3 (en) Tricyclic farnesyl protein transferase inhibitors
US5945430A (en) Aminooxyamide tricyclic inhibitors of farnesyl-protein transferase
AU2007202115A1 (en) Tricyclic antitumor compounds being farnesyl protein transferase inhibitors
MXPA01006241A (en) Tricyclic farnesyl protein transferase inhibitors

Legal Events

Date Code Title Description
FC9A Refused patent application